AzTrials
AzTrials

Multiple Sclerosis, Relapsing-RemittingPhase 2INCREASENCT03387046

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

A Phase 2 study testing D-aspartate, IFN beta-1a and Methylprednisolone in people with Multiple Sclerosis, Relapsing-Remitting, run by Merck KGaA, Darmstadt, Germany at 17 sites in Italy.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy. Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Multiple Sclerosis, Relapsing-Remitting
What is being tested?
D-aspartate, IFN beta-1a and Methylprednisolone
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
7 participants
Where
17 sitesItaly
Study dates
26 Mar 2018to 11 Jan 2019
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Participants with RR-MS, according to the revised McDonald Criteria (2010)
  • Participants with an expanded disability status scale (EDSS) score between 0 and 3 before screening visit and before relapse
  • Participants receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6 months but for no more than 10 years before the screening visit
  • Female participants must be neither pregnant nor breastfeeding and must lack childbearing potential
  • Participants willing and able to comply with the protocol for the total duration of the study
  • Participants able to understand the purposes and the risks of the study
Show all 11Show fewer
  • Participants have signed the appropriate written informed consent form, approved by the Independent Ethics Committee (IEC), prior to the performance of any study activities
  • For MS participants with relapse:
  • Deterioration of at least one step in a relevant Functional Systems Scale (FSS) or an increase in EDSS of 1 point or more compatible, according to physician's judgment, with the therapy prosecution
  • Relapse started within maximum 5 days before the inclusion in the study
  • MS participants without relapse with clinically stable RR-MS

Who cannot join

  • Participants with diagnosis of primary progressive MS (PP-MS)
  • Participants have any disease other than MS that could better explain his/her signs and symptoms
  • Participants with any comorbidity with diseases that might alter synaptic plasticity (example Parkinson Disease, Alzheimer Disease, Stroke)
  • Participants receiving concomitant treatment with drugs that may alter synaptic plasticity (example, cannabinoids)
  • Participants with history or presence of any unstable medical condition (tumor or chronic infection or severe life threatening infection within the last 6 months)
  • Participants who have received any corticosteroids therapy within 3 months prior to the screening
Show all 20Show fewer
  • Participants with any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressive agents during the course of the study
  • Participants who have received any immunosuppressive agents other to corticosteroids, as monotherapy or combination therapy within 3 months prior to the screening visit
  • Participants with history or currently active primary or secondary immunodeficiency
  • Participants with inadequate liver function, defined by alanine aminotransferase (ALT) > 3 * upper limit of normal (ULN), or alkaline phosphatase (AP) > 2 * ULN, or total bilirubin > 2 * ULN if associated with any elevation of ALT or AP
  • Participants with inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 * lower limit of normal (LLN)
  • Participants with moderate to severe renal impairment
  • Participants unable to complete an magnetic resonance imaging (MRI) (contraindications for MRI include but are not restricted to weight >=140 kilogram (kg), pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc)
  • Participants with contraindication to gadolinium (Gd) can be enrolled into the study but cannot receive Gd contrast dyes during their MRI scans
  • Participants receiving supplements that, in the Investigator's opinion, may affect the evaluation of fatigue
  • Participants with any known contraindications or hypersensitivity to D-aspartate or any excipient
  • Participants with any other significant disease that in the Investigator's opinion would impede study assessments or endanger the participant
  • Female participants with positive pregnancy test at baseline or participants with active project of pregnancy during the study
  • Participants with legal incapacity or limited legal capacity
  • Participants have participated in any other investigational study within 8 weeks before the screening visit

Trial locations and contacts

17 sites in 1 country.

17 sites in 1 country

Italy17 sites
  • Ospedale Binaghi, Università di Cagliari,ASL 8

    Cagliari

  • Ospedale Clinicizzato SS. Annunziata

    Chieti

  • Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate)

    Gallarate

  • Azienda Ospedaliero Universitaria San Martino

    Genova

  • Ospedale P.A.Micone

    Genova

  • Ospedale San Raffaele

    Milan

  • A.O.U. Federico II

    Naples

  • Azienda Ospedaliera di Rilievo Nazionale A. CardarelliAzienda Ospedaliera di Rilievo Nazionale A. Cardarelli

    Naples

  • Seconda Università degli Studi di Napoli

    Naples

  • Azienda Ospedaliera di Padova

    Padova

  • I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo

    Pozzilli

  • Azienda Ospedaliera San Camillo Forlanini

    Roma

  • Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza

    Roma

  • Policlinico Universitario Agostino Gemelli

    Roma

  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata

    Rome

  • Ospedale S. Paolo

    Savona

  • Azienda Ospedaliero Universitaria Ospedali Riuniti

    Torrette Di Ancona

Other trials in Italy

About this study

Official title: Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)

The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.

Being tested
D-aspartate, Placebo, IFN beta-1a, Methylprednisolone
Keywords
Relapsing remitting multiple sclerosis, D-Aspartate, interferon beta-1a
Medical subject headings
Multiple Sclerosis, Relapsing-Remitting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • D-aspartateDietary supplement

    D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.

  • PlaceboDrug

    Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.

  • IFN beta-1aBiological

    IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.

  • MethylprednisoloneDrug

    Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.

Study groups in NCT03387046
Study groupRoleWhat they receive
D-aspartate + IFN beta-1a + MethylprednisoloneExperimentalParticipants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
Receives: Dietary Supplement: D-aspartate; Biological: IFN beta-1a; Drug: Methylprednisolone
Placebo + IFN beta-1a + MethylprednisolonePlacebo comparatorParticipants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
Receives: Drug: Placebo; Biological: IFN beta-1a; Drug: Methylprednisolone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8

    EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).

    Measured: Baseline, Week 8

Secondary outcomes (9)
  1. Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24

    EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).

    Measured: Baseline, Week 12 and 24

  2. 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome.

    Measured: At Week 8, 12 and 24

  3. 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome.

    Measured: Week 8, 12 and 24

  4. Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome.

    Measured: At Week 8, 12 and 24

  5. Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome.

    Measured: Week 8, 12 and 24

  6. Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24

    MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome.

    Measured: Week 8, 12 and 24

  7. Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24

    Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome.

    Measured: Week 8, 12 and 24

  8. Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)

    TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold [RMT]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome.

    Measured: Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8

  9. Number of Treated Participants With Immune-metabolic Response of Lymphocytes

    Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported.

    Measured: Baseline, Week 8 and 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Dec 2017
  2. Study start26 Mar 2018
  3. Primary completion11 Jan 2019
  4. Study completion11 Jan 2019

Why it stopped: Study was terminated early due to slow recruitment rate.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03387046
Sponsor's protocol ID
MS200136_0041
Acronym
INCREASE
Status last verified
Feb 2020
First submitted
22 Dec 2017
Last updated
10 Feb 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing D-aspartate, IFN beta-1a and Methylprednisolone in people with Multiple Sclerosis, Relapsing-Remitting, run by Merck KGaA, Darmstadt, Germany at 17 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 10 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 17 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Feb 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8 (time frame: Baseline, Week 8). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in